Needham & Company
View Older Stories
-
AtriCure Inc. (ATRC) PT Raised to $45 at Needham
-
AtriCure Inc. (ATRC) PT Lowered to $44 at Needham
-
Needham Reiterates Buy Rating on AtriCure Inc. (ATRC)
-
Needham Reiterates Buy Rating on AtriCure Inc. (ATRC)
-
Needham Reiterates Buy Rating on AtriCure Inc. (ATRC)
-
AtriCure Inc. (ATRC) PT Raised to $51 at Needham
-
Needham Reiterates Buy Rating on AtriCure Inc. (ATRC)
-
AtriCure Inc. (ATRC) PT Lowered to $40 at Needham
-
AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference
-
Needham on AtriCure Inc. (ATRC): 'news could create an overhang for ATRC shares'
-
Boston Scientific (BSX) PT Raised to $65 at Needham & Company; Added to Conviction List
-
AtriCure to Participate at Upcoming Investor Conferences
-
AtriCure to Participate in the 22nd Annual Needham Virtual Healthcare Conference
-
AtriCure Inc. (ATRC) PT Raised to $58 at Needham & Company, adds to Conviction List
-
AtriCure to Participate at Upcoming Investor Conferences
-
AtriCure Inc. (ATRC) PT Lowered to $55 at Needham & Company
-
AtriCure Inc. (ATRC) Growth Gets a Boost From cryoSPHERE - Needham & Company
-
AtriCure Inc. (ATRC) PT Raised to $92 at Needham & Company
-
AtriCure's (ATRC) Amaze Trial Represents a Significant Opportunity, Needham Frames the Importance and Timelines
-
AtriCure Inc. (ATRC) PT Raised to $91 at Needham & Company on FDA Approval
-
AtriCure Inc. (ATRC) PT Raised to $81 at Needham & Company
-
AtriCure Inc. (ATRC) Reiterated Top Pick, PT Raised to $74 at Needham & Company Post Earnings
-
AtriCure Inc. (ATRC) Highlighted as Top SMid Healthcare Pick, PT Raised to $63 at Needham
-
AtriCure to Participate in the 39th Annual J.P. Morgan Healthcare Conference
-
AtriCure to Participate at Upcoming Investor Conferences
-
AtriCure (ATRC) Prices 3.98M Share Common Offering at $44/Sh
-
AtriCure Announces Pricing of Public Offering of Common Stock
-
AtriCure (ATRC) Announces Proposed $100M Share Common Offering
-
AtriCure Announces Proposed Public Offering of Common Stock
-
AtriCure Inc. (ATRC) PT Raised to $52 at Needham After EBITDA Beats Positive Revenue Preannouncement
-
AtriCure Inc. (ATRC) PT Raised to $48 at Needham & Company; Increased Confidence in CONVERGE
-
AtriCure to Present at the Needham & Company’s 18th Annual Healthcare Conference
-
AtriCure Inc. (ATRC) PT Raised to $39 at Needham & Company
-
AtriCure Inc. (ATRC) PT Raised to $36 at Needham & Company
-
UPDATE: AtriCure Inc. (ATRC) PT Raised to $32 at Needham & Company; Potential to Consensus and Upcoming Catalysts
-
AtriCure Inc. (ATRC) PT Raised to $26 at Needham & Company
-
AtriCure to Present at the Needham & Company’s 17th Annual Healthcare Conference
-
AtriCure Inc. (ATRC) PT Raised to $26 at Needham & Company Following 2Q Beat
-
AtriCure (ATRC): Open Heart Ablation Growth Rebounded - Needham
-
AtriCure to Present at the Needham & Company’s 16th Annual Healthcare Conference
-
Needham & Company Cuts Price Target on AtriCure (ATRC) to $20; Reiterates Buy
-
ResMed (RMD), St. Jude (STJ), Cepheid (CPHD) Among Med Tech Companies with Most EU Exposure - Needham & Company
-
Needham & Company Remains Bullish After Meeting with AtriCure (ATRC) Management
-
Needham & Company Raises Price Target on Atricure, Inc. (ATRC) Following Management Meetings
-
AtriCure to Present at the Needham Healthcare Conference
-
AtriCure (ATRC) PT Raised to $26 at Needham & Company Amid NEJM Trial
-
Needham & Company Starts AtriCure Inc. (ATRC) at Buy
-
Needham & Company Reiterates a 'Buy' on AtriCure (ATRC); Positive Takeaways from ISMICS

